ARKF vs XBI
ARK Fintech Innovation ETF vs SPDR S&P Biotech ETF
- • XBI has the lower expense ratio at 0.35% vs 0.75% for ARKF.
- • XBI pays a higher dividend yield (0.34%).
Side-by-side metrics
| Metric | ARKF | XBI |
|---|---|---|
Expense ratio Annual fee. Lower is better. | 0.75% | 0.35% |
Dividend yield Trailing 12-month yield. | 0.10% | 0.34% |
AUM Assets under management — bigger funds are typically more liquid. | $828M | $8.30B |
YTD return | -10.39% | 12.92% |
1-year return | — | — |
3-year return Annualized. | — | — |
5-year return Annualized. | — | — |
10-year return Annualized. | — | — |
Beta (3Y) Volatility relative to the market. Closer to 1 = market-like. | 2.06 | 1.09 |
P/E ratio | 36.52 | — |
Last price | $42.28 | $133.66 |
Inception | — | — |
Issuer | ARK | State Street |
ARKF top holdings
| SHOP | Shopify Inc Registered Shs -A- Subord Vtg | 9.27% |
| COIN | Coinbase Global Inc Ordinary Shares - Class A | 5.83% |
| CRCL | Circle Internet Group Inc Ordinary Shares - Class A | 5.47% |
| XYZ | Block Inc Class A | 5.31% |
| HOOD | Robinhood Markets Inc Class A | 4.47% |
| PLTR | Palantir Technologies Inc Ordinary Shares - Class A | 4.20% |
| TOST | Toast Inc Class A | 4.12% |
| AMD | Advanced Micro Devices Inc | 3.88% |
| AMZN | Amazon.com Inc | 3.87% |
XBI top holdings
| APLS | Apellis Pharmaceuticals Inc | 1.87% |
| RVMD | Revolution Medicines Inc Ordinary Shares | 1.65% |
| TVTX | Travere Therapeutics Inc Ordinary Shares | 1.62% |
| ARWR | Arrowhead Pharmaceuticals Inc | 1.44% |
| TWST | Twist Bioscience Corp | 1.42% |
| SMMT | Summit Therapeutics Inc Ordinary Shares | 1.40% |
| ALKS | Alkermes PLC | 1.38% |
| TGTX | TG Therapeutics Inc | 1.37% |
| MDGL | Madrigal Pharmaceuticals Inc | 1.36% |
| BEAM | Beam Therapeutics Inc | 1.32% |
About ARKF
ARKF (ARK Fintech Innovation ETF) is Fintech companies disrupting financial services. Managed by ARK, the fund carries $828M in assets under management, an expense ratio of 0.75%, a dividend yield of 0.10%. Its largest holding is Shopify Inc Registered Shs -A- Subord Vtg (SHOP), which represents 9.3% of the portfolio. Consumer Cyclical is the fund's largest sector exposure at 16.4%.
About XBI
XBI (SPDR S&P Biotech ETF) is Equal-weight biotech stocks in the S&P Biotech Index. Managed by State Street, the fund carries $8.3B in assets under management, an expense ratio of 0.35%, a dividend yield of 0.34%. Its largest holding is Apellis Pharmaceuticals Inc (APLS), which represents 1.9% of the portfolio. Financial Services is the fund's largest sector exposure at 0.2%.